Computational algorithm-driven evaluation of monocytic myeloid-derived suppressor cell frequency for prediction of clinical outcomes. - Wikidata - wikimedia - TriplyDB

Computational algorithm-driven evaluation of monocytic myeloid-derived suppressor cell frequency for prediction of clinical outcomes.

Computational algorithm-driven evaluation of monocytic myeloid-derived suppressor cell frequency for prediction of clinical outcomes.

http://www.wikidata.org/entity/Q34016867

about

Clinical utility of nivolumab in the treatment of advanced melanoma Novel technologies and emerging biomarkers for personalized cancer immunotherapy Paving the Road to Tumor Development and Spreading: Myeloid-Derived Suppressor Cells are Ruling the Fate Tumor-induced myeloid deviation: when myeloid-derived suppressor cells meet tumor-associated macrophages Clinical Development of Immune Checkpoint Inhibitors.Clinical significance of plasmacytoid dendritic cells and myeloid-derived suppressor cells in melanoma Complexity and challenges in defining myeloid-derived suppressor cells DNA Methylation-Derived Neutrophil-to-Lymphocyte Ratio: An Epigenetic Tool to Explore Cancer Inflammation and Outcomes.2015 Guidance on cancer immunotherapy development in early-phase clinical studies.Phase I/II Study of Metastatic Melanoma Patients Treated with Nivolumab Who Had Progressed after Ipilimumab.Targeting myeloid-derived suppressor cells with colony stimulating factor-1 receptor blockade can reverse immune resistance to immunotherapy in indoleamine 2,3-dioxygenase-expressing tumors Summary and Recommendations from the National Cancer Institute's Clinical Trials Planning Meeting on Novel Therapeutics for Non-Muscle Invasive Bladder Cancer Nivolumab for advanced melanoma: pretreatment prognostic factors and early outcome markers during therapy.Ipilimumab in the treatment of advanced melanoma - a clinical update.On being less tolerant: enhanced cancer immunosurveillance enabled by targeting checkpoints and agonists of T cell activation.Myeloid Derived Suppressor Cells: Fuel the Fire.The future of cancer treatment: immunomodulation, CARs and combination immunotherapy.Biomarkers associated with checkpoint inhibitors.Myeloid-derived suppressor cells as intruders and targets: clinical implications in cancer therapy.A clinical and biological perspective of human myeloid-derived suppressor cells in cancer.Targeting KIT on innate immune cells to enhance the antitumor activity of checkpoint inhibitors.Targeting the tumor microenvironment to improve natural killer cell-based immunotherapies: On being in the right place at the right time, with resilience.Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy.Immune biomarkers for chronic inflammation related complications in non-cancerous and cancerous diseases.High Absolute Monocyte Count Predicts Poor Clinical Outcome in Patients with Castration-Resistant Prostate Cancer Treated with Docetaxel Chemotherapy.Immunotherapy of cancers comes of age.Role of Tumor Pericytes in the Recruitment of Myeloid-Derived Suppressor Cells.Increases in Absolute Lymphocytes and Circulating CD4+ and CD8+ T Cells Are Associated with Positive Clinical Outcome of Melanoma Patients Treated with Ipilimumab.Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab.Predictors of responses to immune checkpoint blockade in advanced melanoma Biomarkers for Response of Melanoma Patients to Immune Checkpoint Inhibitors: A Systematic Review.Clinical implication of tumor-associated and immunological parameters in melanoma patients treated with ipilimumab.Transcriptional profiling of whole blood: a rich source of immune biomarkers in cancer.Immune Activation in Early-Stage Non-Small Cell Lung Cancer Patients Receiving Neoadjuvant Chemotherapy Plus Ipilimumab.Tumor immunology and cancer immunotherapy: summary of the 2014 SITC primer.Serial pseudoprogression of metastatic malignant melanoma in a patient treated with nivolumab: a case report.The ratio of HLA-DR and VNN2+ expression on CD14+ myeloid derived suppressor cells can distinguish glioblastoma from radiation necrosis patients.Relationships between lymphocyte counts and treatment-related toxicities and clinical responses in patients with solid tumors treated with PD-1 checkpoint inhibitors.Efficacy and immune activation of ipilimumab in early-stage lung cancer patients.Biomarkers for Immune Checkpoint Inhibitors in Melanoma

P2860

Q26751268-65D112FC-996B-4BE8-8AD2-6017936CABC3 Q26770780-ECFFDCA6-0098-4268-A98D-22949956C40E Q26777205-07888C00-94F8-4F5F-BB2B-A72BF0711ADB Q34044797-9676C120-0CC2-467B-AEF0-FDCDF10AAE6C Q34671498-BD824538-DA01-416C-BCDC-8F616828C251 Q35078852-B58F677A-394D-4D68-BD9F-388E663ECC92 Q35509317-2A9D8ED7-FBFD-4E1A-8441-53B6AB82FCB1 Q36222815-34C3CC41-7723-4EC3-B8E8-551A9F7E701E Q36467378-54AA9B7F-F0DF-484D-A1EB-A3CDB10E0494 Q36759111-359F6B6B-9441-4CF5-BA80-441D6D9270E8 Q36869880-E81EAF8D-486B-485F-A5B2-8CA2C2AFBAC2 Q37053820-1F57B4A5-94C5-4F35-9CC3-3581540FBF8C Q37718376-BB3AD3C2-AD4F-4DE5-BAC5-FDCE638B3F56 Q38253823-0F8F80C0-6B31-4EEC-8249-F3B8AE516ED1 Q38391533-DD875573-1F92-42A1-A907-E586A4BAC2C5 Q38613648-A0503D4D-3CD2-40F2-B03E-6755BA0B39EA Q38775177-FF61CFF5-D57F-44A5-A592-4FD4D88280BE Q38819537-4C5BF439-80D5-450A-AABE-11A280DFA32A Q38844417-90F2CCFE-8344-4FB5-A7EA-55046041F579 Q38847251-28994228-D1B6-4B9B-85FA-7B8ADF3F4CDE Q38878888-AF2ED7C6-D467-45E4-ACA5-4A36DB363540 Q39281940-7B790B9A-8AF3-431A-A1C8-36B668810DBD Q39313889-3290B20A-2297-4DFD-8326-8C4D6930BC69 Q39412983-B47EE160-B4CD-47BF-A9E0-AC632AC4F66A Q39641273-F3A5EAA6-89DC-4AF2-A80F-83C18280143F Q40099075-436D5980-69DA-4E7C-BD69-14E1A0039071 Q40619105-6A8400D3-96D3-456C-858F-42C644274D9D Q40758666-8F87CE4A-B5F7-4868-9A14-89853AC20F76 Q40964128-00918964-1581-4EC1-A808-0BBE664C4C36 Q41701241-E2A338F4-885C-4F74-8B92-13D66D6E2718 Q42369277-9C557D6A-4C72-413C-8723-EA8727168995 Q42968783-F79EC200-E003-4FF3-9F4A-F207AEC2DE41 Q43103780-0BC66B63-127E-4A8F-8500-1A3812E3CE0B Q45959320-4C246ED1-FCA1-4210-BEF7-AC2886CCAC65 Q46090703-E2439438-AD8D-4C3D-BF4C-9215D42AF8A6 Q47096567-B51C2E82-EDD7-4146-9D29-EC83DB0A6327 Q48367212-F868292F-A1FE-4D8F-8CDB-AFCE6CAE14E0 Q49593797-F3B22627-C20D-4929-8548-816535C82E25 Q55709749-D19FE200-B227-4E5A-BF37-A9E12CA9DAC5 Q57175477-B8F000B1-0406-48BB-90F2-FA4C3494183E

P2860

Computational algorithm-driven evaluation of monocytic myeloid-derived suppressor cell frequency for prediction of clinical outcomes.

http://www.wikidata.org/entity/Q34016867

description

2014 nî lūn-bûn

@nan

2014 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Computational algorithm-driven ...... ediction of clinical outcomes.

@ast

Computational algorithm-driven ...... ediction of clinical outcomes.

@en

Computational algorithm-driven ...... ediction of clinical outcomes.

@nl

type

label

Computational algorithm-driven ...... ediction of clinical outcomes.

@ast

Computational algorithm-driven ...... ediction of clinical outcomes.

@en

Computational algorithm-driven ...... ediction of clinical outcomes.

@nl

prefLabel

Computational algorithm-driven ...... ediction of clinical outcomes.

@ast

Computational algorithm-driven ...... ediction of clinical outcomes.

@en

Computational algorithm-driven ...... ediction of clinical outcomes.

@nl

P1433

Q34016867-D066968E-767E-4B41-AE59-F51A848A4521

P1476

Q34016867-0A6E8994-DC09-4E38-A73E-EBF0D7E53D13

P2093

Q34016867-23D35B0D-A95A-4ADA-B885-6CC95D5A0325

Q34016867-2A9E122A-ACEC-4024-A2B6-B3D3C37B87BF

Q34016867-3BDC3811-A6EB-45C2-A1B1-356DEB2FFB67

Q34016867-4638C932-5AAA-4BC8-BEC7-AD9A17253978

Q34016867-4B014200-82D3-41CB-8C38-FC7268632102

Q34016867-5CCB27C1-3C7E-4F11-B009-CF7354D99025

Q34016867-78718D2B-B7C0-4B45-8B92-560BC418FFA6

Q34016867-B29594E4-217D-4EA5-ACBB-5592B44F0E40

P2860

Q34016867-0B935C97-E0BB-4442-B846-232794B345B2

Q34016867-0DAB87BA-09BF-4198-B2BD-24D8310BF975

Q34016867-117EC20C-AA95-4020-A374-5AA4C9A5112E

Q34016867-14E64BDF-8618-4B56-93CA-440BE85CDD1D

Q34016867-18E27104-92C4-47C3-BF46-6CCB8A882EEF

Q34016867-20ADDAEA-E3F1-4592-B97A-0515BA40F793

Q34016867-2984F26C-8FBF-4B02-81B8-1F38C4D0526E

Q34016867-2E19EF4E-8E9B-442F-AF64-58C6D69F33C5

Q34016867-34CFA43A-4BC1-4146-87B4-5FF5ADC04426

Q34016867-3BDB88C8-C7F0-48E4-AAB7-B278700BE987

P304

Q34016867-6907A2A1-00C2-420F-A215-BBA189F32901

P31

Q34016867-02FE8B14-4BE2-4435-AE55-D77EA59EAEEC

P356

Q34016867-4F16F74C-2F7B-4040-A046-1E1E9A39D1EF

P433

Q34016867-51AB5070-00E9-47B4-B73D-B1C57B1E94F6

P478

Q34016867-A09FCA88-6A9D-4B54-B695-EDE2942CBA37

P50

Q34016867-175AEA16-9F58-4F42-AB3C-FDD6BB049503

Q34016867-8847F4EF-830B-49E6-B55F-2669652CC632

Q34016867-C5868E20-CC12-4729-93C8-485251DD9BD8

Q34016867-CE795CC5-99F8-4E7D-9082-7184DF670FF2

Q34016867-D9210290-1CEE-400D-B203-2F036855447F

P577

Q34016867-F8B45B07-9680-485B-B2F7-6E28B167BDA9

P698

Q34016867-004AA661-62C3-4926-99AD-6BBD05A41635

P932

Q34016867-4AB78F1E-013C-4199-8E7A-F4AC13FAF07D

P356

2326-6066.CIR-14-0013

P1433

Cancer immunology research

P1476

Computational algorithm-driven ...... ediction of clinical outcomes.

@en

P2093

Alexander M Lesokhin

http://www.w3.org/2001/XMLSchema#string

Czrina Cortez

http://www.w3.org/2001/XMLSchema#string

Jedd D Wolchok

http://www.w3.org/2001/XMLSchema#string

Jianda Yuan

http://www.w3.org/2001/XMLSchema#string

Katherine S Panageas

http://www.w3.org/2001/XMLSchema#string

Michael A Postow

http://www.w3.org/2001/XMLSchema#string

Shigehisa Kitano

http://www.w3.org/2001/XMLSchema#string

Teresa Rasalan

http://www.w3.org/2001/XMLSchema#string

P2860

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

Myeloid-derived suppressor cells as regulators of the immune system

Coordinated regulation of myeloid cells by tumours

Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function

Immunologic correlates of the abscopal effect in a patient with melanoma

Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials.

Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival

Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial.

Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study.

P304

812-821

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/2326-6066.CIR-14-0013

http://www.w3.org/2001/XMLSchema#string

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

2

http://www.w3.org/2001/XMLSchema#string

P50

Grégoire Altan-Bonnet

Carly G K Ziegler

P577

2014-05-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24844912

http://www.w3.org/2001/XMLSchema#string

P932

4125466

http://www.w3.org/2001/XMLSchema#string